Skip To Main Content
Maame Esi Ackon on Muck Rack

Maame Esi Ackon

As seen in: Cell Reports Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maame Esi

Contact Maame Esi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer

|
By Sally E. Claridge, Majd Al Assaad, Eric Park, Julie-Ann Cavallo, Lamberto De Boni, Stacey Baker, Stephanie V. Blank, Olivier Elemento, Rachel Brody Verified, Benjamin Hopkins, Shalini Nath, Genesis Lara Granados, Ufuoma Nuwere, Maame Esi Ackon, E. Premkumar Reddy
| Cell Reports Medicine Verified
Keywords ovarian cancer rigosertib precision oncology high-throughput drug screening Kinome Atlas PI3K/MAPK signaling Introduction Ovarian cancer has a devastating impact, accounting for approximately 207,252 deaths and a total of 313,959 new cases worldwide in 2020.1 Data from the American Cancer Society estimated that 19,680 new ovarian cancer diagnoses and 12,740 fatalities will occur in the United States in 2024.2 Projections also suggest that, by 2040, the patient population with ovarian...
Open in Who Shared Issue with article?
See all 1 articles